Skip to content

Effects of Transcranial Direct Current Stimulation (tDCS) on Neuropathic Symptoms Due to Burn Injury

Cortical Modulation With Transcranial Direct Current Stimulation (tDCS) for Neuropathic Symptoms Following Burn Injury.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01404026
Enrollment
3
Registered
2011-07-27
Start date
2011-06-30
Completion date
2012-01-31
Last updated
2020-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn Injury, Pain

Keywords

Transcranial Direct Current Stimulation

Brief summary

The purpose of this study is to investigate the effects of transcranial direct current stimulation (tDCS) on the neuropathic symptoms (pain/itch) due to a burn injury. The investigators hypothesize that the active tDCS group will show a significant pain/itch reduction when compared to sham stimulation.

Interventions

DEVICETranscranial Direct Current Stimulation (tDCS)

Subjects will undergo tDCS stimulation. For both active and sham stimulation we will use electrodes at 35cm\^2, with an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex, and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be active for the duration of 20 minutes. For sham stimulation, the current will only be active for 30 seconds, simulating the sensations of active stimulation.

Sponsors

Spaulding Rehabilitation Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

STUDY ELIGIBILITY CRITERIA: 1. Providing informed consent to participate in the study 2. 18 to 64 years old 3. Any size closed wound from burn injury, occurring at least 3 weeks prior to enrollment in the study. \- Subjects with burns in scalp area will be excluded from the study as the electrode may cause irritation to the injuries 4. Use of regular medications for pain and/or itching control at stable doses for at least 3 weeks prior to enrollment in the study 5. No contraindications to tDCS: * metallic implants in the head * implanted brain medical devices 6. Subject is not pregnant at the time of enrollment 7. Neuropathic pain or itching (rated at least 4 on the VAS) within the burn scar or donor site, (pain can be described as burning, stabbing, piercing, pins and needles, tearing sensation) for at least 3 weeks. Please note: If a patient reports pain and itching, we will enroll the patient based upon their most dominant symptom.

Design outcomes

Primary

MeasureTime frameDescription
Effect of tDCS on pain/itch perceptionMeasured for approximately 2 weeksDetermine whether active tDCS offers a greater benefit on pain reduction in patients with neuropathic symptoms (itch/pain) following burns as compared with sham tDCS. We hypothesize that active tDCS will be associated with a larger pain/itch reduction, as indexed by the Visual Analogue Scale for Pain/Itch (VAS). The subject's VAS score will be measured immediately before the tDCS stimulation sessions and after the tDCS stimulation sessions for the duration of their participation in the trial.

Secondary

MeasureTime frameDescription
Effect of tDCS on motor cortex excitabilityMeasured for approximately 2 weeks.To investigate whether active tDCS induces changes in motor cortex and spinal cord excitability as indexed by single and paired-pulse transcranial magnetic stimulation (TMS) as compared with sham tDCS. We will also determine whether these changes are correlated with the clinical outcome (pain/itch reduction). The subject's cortical excitability will be measured immediately before the tDCS stimulation sessions and after the tDCS stimulation sessions for the duration of their participation in the trial.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026